Indium-111-octreotide scintigraphy, intraoperative gamma-detector localisation and somatostatin receptor expression in primary human breast cancer.

Abstract:

:12 women with primary breast cancer underwent somatostatin receptor scintigraphy (SRS) with 111In-DTPA-D-Phe1-octreotide. The tumour sizes varied between 2 and 5 cm and were all, except one, palpable at clinical examination. Tumour biopsies were taken with additional sampling from normal breast tissue, fat, muscle, axillary lymph nodes and peripheral blood. Ratios between the 111In activity concentration in the tissue biopsies (Ti) and in peripheral blood (B) as well as in normal breast tissue (Br) were calculated. In 8/12 patients the scintillation detector was used intraoperatively for radioactivity measurements of the biopsies in situ and ex vivo. The sstr-subtype profiles were determined by northern blot analysis and the relative expression of sstr2 by ribonuclease protection assay (RPA) and immunocytochemistry. Preoperative SRS visualised all primary breast cancer tumours. The scintigraphic image showed no correlation with the histopathological type of the tumour or with the abundance of oestrogen/progesterone receptors on the tumour. Two patients with a massive tumour infiltration of the lymph nodes had a distinct positive SRS of the ipsilateral axilla. In one patient with three nodal metastases the scintigraphic image of the axilla was weak but visible. Four other patients with a negative axillary scintigraphy had 1-2 lymph node metastases. The Ti/B ratios for the breast tumours varied between four and 33 and were not different from Ti/Br ratios. In lymph node metastases the Ti/B ratios were higher (10-41). Intraoperative detector measurements showed a significant difference between the breast tumour and normal tissue in 2/8 patients in situ. Similar measurements on excised tissues (ex vivo) showed a significant difference in 6/8 patients. Two patients with lymph node metastases exhibited a significantly increased uptake ex vivo by detector measurements, but in only one of them in situ. All tumour biopsies expressed the presence of sstrl, 3, 4 and 5, but not of sstr2 at northern analysis. On the other hand, sstr2 was detected in all tumours by RPA and immunocytochemistry. Preoperative SRS visualised primary breast cancer lesions in all 12 patients. SRS could also demonstrate extensive axillary tumour infiltration. Intraoperative use of the scintillation detector could not exclude axillary metastases in situ. The low Ti/B values of both primary tumours and metastases indicate limitations of the radiopharmaceutical used.

authors

Skånberg J,Ahlman H,Benjegård SA,Fjälling M,Forssell-Aronsson EB,Hashemi SH,Nilsson O,Suurkula M,Jansson S

doi

10.1023/a:1016120529858

subject

Has Abstract

pub_date

2002-07-01 00:00:00

pages

101-11

issue

2

eissn

0167-6806

issn

1573-7217

journal_volume

74

pub_type

杂志文章
  • Syndecan-1 facilitates breast cancer metastasis to the brain.

    abstract:PURPOSE:Although survival rates for patients with localized breast cancer have increased, patients with metastatic breast cancer still have poor prognosis. Understanding key factors involved in promoting breast cancer metastasis is imperative for better treatments. In this study, we investigated the role of syndecan-1 ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-019-05347-0

    authors: Sayyad MR,Puchalapalli M,Vergara NG,Wangensteen SM,Moore M,Mu L,Edwards C,Anderson A,Kall S,Sullivan M,Dozmorov M,Singh J,Idowu MO,Koblinski JE

    更新日期:2019-11-01 00:00:00

  • A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer.

    abstract::Heat shock protein 90 (Hsp90) facilitates maturation and stability of HER2. Combining an Hsp90 inhibitor and trastuzumab has demonstrated anti-tumor effects in patients with HER2+ breast cancer. Adults with measurable, locally advanced or metastatic HER2+ breast cancer and prior trastuzumab treatment were enrolled in ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s10549-013-2510-5

    authors: Modi S,Saura C,Henderson C,Lin NU,Mahtani R,Goddard J,Rodenas E,Hudis C,O'Shaughnessy J,Baselga J

    更新日期:2013-05-01 00:00:00

  • The association between HSD17B1 Ser312Gly polymorphism and breast cancer risk: a meta-analysis including 31,053 subjects.

    abstract::There are increasing evidences that HSD17B1 plays a significant role in the development of breast cancer. However, published data on the association between HSD17B1 Ser312Gly polymorphism and breast cancer risk are inconclusive. In order to derive a more precise estimation of this relationship, a meta-analysis includi...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析

    doi:10.1007/s10549-010-0784-4

    authors: Yao L,Cao LH,Qiu LX,Yu L

    更新日期:2010-09-01 00:00:00

  • Breast cancer screening using tomosynthesis in combination with digital mammography compared to digital mammography alone: a cohort study within the PROSPR consortium.

    abstract::Digital breast tomosynthesis (DBT) is emerging as the new standard of care for breast cancer screening based on improved cancer detection coupled with reductions in recall compared to screening with digital mammography (DM) alone. However, many prior studies lack follow-up data to assess false negatives examinations. ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-016-3695-1

    authors: Conant EF,Beaber EF,Sprague BL,Herschorn SD,Weaver DL,Onega T,Tosteson AN,McCarthy AM,Poplack SP,Haas JS,Armstrong K,Schnall MD,Barlow WE

    更新日期:2016-02-01 00:00:00

  • Receptor activator of nuclear factor kappa B (RANK) expression in primary breast cancer correlates with recurrence-free survival and development of bone metastases in I-SPY1 (CALGB 150007/150012; ACRIN 6657).

    abstract:PURPOSE:The receptor activator of nuclear factor kappa B (RANK)/RANK ligand (RANKL)/osteoprotegerin (OPG) axis may contribute to the development of bone metastases (BM). We studied gene expression in this pathway in primary breast cancer (BC) to determine correlations with clinical characteristics and outcomes in the n...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1007/s10549-017-4318-1

    authors: Vidula N,Yau C,Li J,Esserman LJ,Rugo HS

    更新日期:2017-08-01 00:00:00

  • Survival analysis of censored data: neural network analysis detection of complex interactions between variables.

    abstract::Neural networks can be used as pattern recognition systems in complex data sets. We are exploring their utility in performing survival analysis to predict time to relapse or death. This technique has the potential to find easily some types of very complex interactions in data that would not be easily recognized by con...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF00666212

    authors: De Laurentiis M,Ravdin PM

    更新日期:1994-01-01 00:00:00

  • Androgens inhibit basal and estrogen-induced cell proliferation in the ZR-75-1 human breast cancer cell line.

    abstract::This study describes the inhibitory effect of 5 alpha-dihydrotestosterone (5 alpha-DHT) and its precursors testosterone (T) and androst-4-ene-3,17-dione (delta 4-DIONE) on the growth of the estrogen-sensitive human breast cancer cell line ZR-75-1. In the absence of estrogens, cell proliferation measured after a 12-day...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01805942

    authors: Poulin R,Baker D,Labrie F

    更新日期:1988-10-01 00:00:00

  • Trends in the incidence rate and risk factors for breast cancer in Japan.

    abstract::The incidence rate of breast cancer in Japan rose more than two-fold from 1959-60 to 1983-87. To assess to what extent this increase can be explained by changes in the prevalence of four major risk factors of breast cancer (i.e. age at menarche, age at first birth, age at menopause, and parity), we estimated the proba...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1005726110649

    authors: Nagata C,Kawakami N,Shimizu H

    更新日期:1997-05-01 00:00:00

  • Gene-based analysis of the fibroblast growth factor receptor signaling pathway in relation to breast cancer in African American women: the AMBER consortium.

    abstract::We conducted gene-based analysis in 26 genes in the FGFR signaling pathway to identify genes carrying genetic variation affecting risk of breast cancer and the specific estrogen receptor (ER) subtypes. Tagging single-nucleotide polymorphisms (SNPs) for each gene were selected and genotyped on a customized Illumina Exo...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-015-3672-0

    authors: Ruiz-Narváez EA,Haddad SA,Lunetta KL,Yao S,Bensen JT,Sucheston-Campbell LE,Hong CC,Haiman CA,Olshan AF,Ambrosone CB,Palmer JR

    更新日期:2016-01-01 00:00:00

  • Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.

    abstract:BACKGROUND:Breakthrough progress has been made in Cyclin-Dependent kinase 4 and 6 (CDK4/6) inhibitors when combined with endocrine therapy (ET) for hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC). Though significant improvements of progression-free survival (PFS) for CDK4/6 inhibitor...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析,评审

    doi:10.1007/s10549-020-05528-2

    authors: Li J,Fu F,Yu L,Huang M,Lin Y,Mei Q,Lv J,Wang C

    更新日期:2020-02-01 00:00:00

  • Microsatellite genotyping reveals a signature in breast cancer exomes.

    abstract::Genomic instability at microsatellite loci is a hallmark of many cancers, including breast cancer. However, much of the genomic variation and many of the hereditary components responsible for breast cancer remain undetected. We hypothesized that variation at microsatellites could provide additional genomic markers for...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-014-2908-8

    authors: McIver LJ,Fonville NC,Karunasena E,Garner HR

    更新日期:2014-06-01 00:00:00

  • Introduction of hsa-miR-512-3p as a new regulator of HER2 signaling pathway in breast cancer.

    abstract:PURPOSE:Dysregulation of HER2 signaling pathway in breast cancer is well documented. Our bioinformatics analysis predicted hsa-miR-512-3p (miR-512-3p) as a bona fide regulator of HER2 as well as HER3, PIK3R2, and AKT1 genes. Then, we intended to examine the effect of miR-512-3p on the predicted target genes that are in...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05937-3

    authors: Mohamadzade Z,Mahjoubi F,Soltani BM

    更新日期:2021-01-01 00:00:00

  • Dual-colour CISH is a reliable alternative to FISH for assessment of topoisomerase 2-alpha amplification in breast carcinomas.

    abstract::Anthracyclines are among the most powerful antineoplastic drugs available for breast cancer treatment. Although HER2 amplification has been postulated to predict anthracycline benefit, numerous reports have demonstrated that HER2/TOP2A co-amplification is the clinically useful predictive marker of response to anthracy...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-013-2791-8

    authors: García-Caballero T,Prieto O,Vázquez-Boquete A,Gude F,Viaño P,Otero M,Curiel T,Fernández-Rodríguez B,Parrado C,Fraga M,Antúnez JR

    更新日期:2014-01-01 00:00:00

  • Recurrent and pathological gene fusions in breast cancer: current advances in genomic discovery and clinical implications.

    abstract::Gene fusions have long been considered principally as the oncogenic events of hematologic malignancies, but have recently gained wide attention in solid tumors due to several milestone discoveries and the advancement of deep sequencing technologies. With the progress in deep sequencing studies of breast cancer transcr...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/s10549-016-3876-y

    authors: Veeraraghavan J,Ma J,Hu Y,Wang XS

    更新日期:2016-07-01 00:00:00

  • Fractionated radiosurgery for brain metastases in 43 patients with breast carcinoma.

    abstract::About 15% of metastatic breast carcinoma patients are diagnosed with brain metastases. Historically, the majority are treated with palliative external whole-brain radiation with a median survival of 4 months. We examined stereotactic radiosurgery's effect on treatment outcome in such patients. Four hundred and fifty f...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1006490200335

    authors: Lederman G,Wronski M,Fine M

    更新日期:2001-01-01 00:00:00

  • Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer.

    abstract:BACKGROUND:TOP2A gene encodes topoisomerase II alpha, the direct molecular target of anthracyclines. This gene is frequently coamplified with HER2. The aims of this study were to analyse the pattern of TOP2A amplification and protein expression in relation to the molecular subgroups of breast cancers; and to define the...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-006-9492-5

    authors: Arriola E,Rodriguez-Pinilla SM,Lambros MB,Jones RL,James M,Savage K,Smith IE,Dowsett M,Reis-Filho JS

    更新日期:2007-12-01 00:00:00

  • Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer.

    abstract:AIMS:To determine whether IHC4 score assessed on pre-treatment core biopsies (i) predicts response to neo-adjuvant chemotherapy in ER-positive (ER+) breast cancer; (ii) provides more predictive information than Ki67 alone. METHODS:113 patients with ER+ primary breast cancer treated with neo-adjuvant chemotherapy at th...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4266-9

    authors: Sheri A,Smith IE,Hills M,Jones RL,Johnston SR,Dowsett M

    更新日期:2017-07-01 00:00:00

  • Health disparities in breast cancer: biology meets socioeconomic status.

    abstract::Breast cancer is the most common cancer in women worldwide, accounting for just over 1 million new cases annually. Population-based statistics show that globally, when compared to whites, women of African ancestry (AA) tend to have more aggressive breast cancers that present more frequently as estrogen receptor negati...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/s10549-010-0827-x

    authors: Dunn BK,Agurs-Collins T,Browne D,Lubet R,Johnson KA

    更新日期:2010-06-01 00:00:00

  • Evolution in practice patterns of axillary management following mastectomy in patients with 1-2 positive sentinel nodes.

    abstract:PURPOSE:The optimal management of breast cancer patients with a positive sentinel lymph node (SLN) who undergo mastectomy remains controversial. This study aimed to describe treatment patterns of patients with positive SLNs who undergo mastectomy using a large population-based database. METHODS:The NCDB was queried fo...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-019-05243-7

    authors: Weiss A,Lin H,Babiera GV,Bedrosian I,Shaitelman SF,Shen Y,Kuerer HM,Mittendorf EA,Caudle AS,Hunt KK,Hwang RF

    更新日期:2019-07-01 00:00:00

  • Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer.

    abstract:PURPOSE:In our microarray analysis we observed that Seven-in-Absentia Homolog 2 (SIAH2) levels were low in estrogen receptor (ER) positive breast tumors of patients resistant to first-line tamoxifen therapy. The aim of this study was to evaluate SIAH2 for its (a) predictive/prognostic value, and (b) functional role in ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-008-0125-z

    authors: Jansen MP,Ruigrok-Ritstier K,Dorssers LC,van Staveren IL,Look MP,Meijer-van Gelder ME,Sieuwerts AM,Helleman J,Sleijfer S,Klijn JG,Foekens JA,Berns EM

    更新日期:2009-07-01 00:00:00

  • Measures of energy balance and mammographic density in the Nurses' Health Study.

    abstract::Mammographic density is a strong risk factor for breast cancer; however the mechanism that underlies this association is unclear. We hypothesized that measures of energy balance early in life and in adulthood may be associated with mammographic density. We conducted a cross-sectional analysis of 1,398 women in the Nur...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-007-9631-7

    authors: Samimi G,Colditz GA,Baer HJ,Tamimi RM

    更新日期:2008-05-01 00:00:00

  • Weight changes after adjuvant treatment in Korean women with early breast cancer.

    abstract:BACKGROUND:Weight gain is a common problem in breast cancer patients and is reported to be associated with poorer survival. However, most data are limited to Western women. We evaluated weight changes after adjuvant treatment in Korean women with early breast cancer. METHODS:The authors reviewed the records of 260 pat...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-008-9984-6

    authors: Han HS,Lee KW,Kim JH,Kim SW,Kim IA,Oh DY,Im SA,Bang SM,Lee JS

    更新日期:2009-03-01 00:00:00

  • Growth-inhibitory effect of adiponectin via adiponectin receptor 1 on human breast cancer cells through inhibition of S-phase entry without inducing apoptosis.

    abstract::Adiponectin is one of the most important adipocytokines secreted from adipose tissue. In addition to its effects on glucose and fatty acid metabolism, it has been reported that adiponectin has a direct growth-inhibitory effect on breast cancer cells. However, it still remains to be established how adiponectin affects ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-007-9874-3

    authors: Nakayama S,Miyoshi Y,Ishihara H,Noguchi S

    更新日期:2008-12-01 00:00:00

  • Clinical relevance and low tumor-initiating properties of oligometastatic breast cancer in pulmonary metastasectomy.

    abstract::Metastatic breast cancer is a systemic disease. However, certain subsets of patients, such as those with oligometastatic breast cancer (OMBC), have long-term survival prospects. Our aim was to evaluate the clinical relevance of OMBC in pulmonary metastasectomy of recurrent breast cancer. We also investigated lung meta...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-014-3111-7

    authors: Mimoto R,Kobayashi T,Imawari Y,Kamio M,Kato K,Nogi H,Toriumi Y,Hirooka S,Uchida K,Takeyama H

    更新日期:2014-09-01 00:00:00

  • Factors influencing the use of extended adjuvant endocrine therapy.

    abstract:PURPOSE:Extending adjuvant endocrine therapy (ET) beyond 5 years has been shown to improve outcomes in breast cancer; however, limited data are available about if and why women pursue extended ET. The primary objective was to estimate the proportion of women who were willing to receive extended ET if recommended by the...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-019-05145-8

    authors: Kadakia KC,Kidwell KM,Barton DL,Schott AF,Hayes DF,Griggs JJ,Henry NL

    更新日期:2019-05-01 00:00:00

  • Fertility preservation does not delay the initiation of chemotherapy in breast cancer patients treated with adjuvant or neo-adjuvant chemotherapy.

    abstract:PURPOSE:To investigate whether fertility preservation (FP) in adult women diagnosed with breast cancer (BC) may impact the time interval between diagnosis and start of chemotherapy in an adjuvant or neo-adjuvant setting. METHODS:Retrospective cohort study of breast cancer patients diagnosed between January 2012 and De...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05858-1

    authors: D'Hondt C,Vanhoeij M,Van Moer E,Segers I,Fontaine C,Tournaye H,De Vos M

    更新日期:2020-11-01 00:00:00

  • ErbB-2 protein in sera and tumors of breast cancer patients.

    abstract::We compared levels of erbB-2 oncoprotein among three groups: Group I included 60 asymptomatic women; Group II had 51 women with benign breast biopsies; and Group III had 67 women with node-negative breast cancer. Serological levels of erbB-2 protein were measured in all participants; tumor levels were measured for Gro...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1006033214721

    authors: Breuer B,Smith S,Thor A,Edgerton S,Osborne MP,Minick R,Cody HS 3rd,Nowak E,Cortese A,Simmons RM,Carney WP,Brandt-Rauf PW

    更新日期:1998-06-01 00:00:00

  • Who may benefit from preoperative breast MRI? A single-center analysis of 1102 consecutive patients with primary breast cancer.

    abstract::Several authors question the potential benefit of preoperative magnetic resonance imaging (MRI) against the background of possible overdiagnosis, false-positive findings, and unnecessary resections in patients with newly diagnosed breast cancer. In order to reveal a better selection of patients who should undergo preo...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-015-3556-3

    authors: Debald M,Abramian A,Nemes L,Döbler M,Kaiser C,Keyver-Paik MD,Leutner C,Höller T,Braun M,Kuhl C,Kuhn W,Schild HH

    更新日期:2015-10-01 00:00:00

  • Isolation and characterization of a breast progenitor epithelial cell line with robust DNA damage responses.

    abstract::We report the establishment of a breast epithelial cell model that undergoes growth arrest at different stages of the cell cycle depending upon the DNA damaging agents encountered. Primary breast epithelial cells from normal reductive mammoplasty were grown in low-calcium culture medium. Free-floating cells under this...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-006-9173-4

    authors: Shen KC,Miller F,Tait L,Santner SJ,Pauley R,Raz A,Tainsky MA,Brooks SC,Wang YA

    更新日期:2006-08-01 00:00:00

  • The impact of rehabilitation support services on health-related quality of life for women with breast cancer.

    abstract::As the number of women surviving breast cancer increases, with implications for the health system, research into the physical and psychosocial sequelae of the cancer and its treatment is a priority. This research estimated self-reported health-related quality of life (HRQoL) associated with two rehabilitation interven...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-005-5151-5

    authors: Gordon LG,Battistutta D,Scuffham P,Tweeddale M,Newman B

    更新日期:2005-10-01 00:00:00